X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1152) 1152
Publication (159) 159
Book Chapter (17) 17
Book Review (10) 10
Conference Proceeding (8) 8
Streaming Video (4) 4
Web Resource (3) 3
Magazine Article (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
eculizumab (937) 937
index medicus (780) 780
humans (712) 712
female (345) 345
complement (328) 328
male (307) 307
antibodies, monoclonal, humanized - therapeutic use (285) 285
hematology (265) 265
complement inhibitor eculizumab (260) 260
hemolytic-uremic syndrome (260) 260
urology & nephrology (252) 252
adult (227) 227
thrombotic microangiopathy (211) 211
atypical hemolytic uremic syndrome (198) 198
transplantation (183) 183
paroxysmal nocturnal hemoglobinuria (165) 165
middle aged (159) 159
treatment outcome (156) 156
diagnosis (150) 150
pediatrics (146) 146
medicine & public health (145) 145
care and treatment (139) 139
paroxysmal-nocturnal hemoglobinuria (132) 132
child (127) 127
immunology (124) 124
therapy (122) 122
adolescent (119) 119
complement activation (118) 118
hemolytic uremic syndrome (116) 116
mutation (116) 116
kidney transplantation (113) 113
activation (112) 112
children (110) 110
hemoglobinuria, paroxysmal - drug therapy (109) 109
thrombosis (108) 108
disease (105) 105
nephrology (105) 105
hemic and lymphatic diseases (104) 104
young adult (104) 104
monoclonal antibodies (102) 102
mutations (101) 101
anemia (100) 100
medicine, general & internal (97) 97
plasma exchange (97) 97
management (94) 94
ahus (93) 93
health aspects (91) 91
thrombotic thrombocytopenic purpura (90) 90
alternative pathway (89) 89
natural-history (89) 89
recurrence (89) 89
hemolysis (88) 88
aged (86) 86
animals (86) 86
patients (83) 83
analysis (80) 80
kidneys (78) 78
research (75) 75
retrospective studies (74) 74
rituximab (74) 74
atypical hemolytic uremic syndrome - drug therapy (73) 73
pregnancy (73) 73
risk factors (73) 73
oncology (72) 72
child, preschool (70) 70
membranoproliferative glomerulonephritis (70) 70
pnh (70) 70
abridged index medicus (69) 69
antibodies, monoclonal, humanized (67) 67
antibodies, monoclonal, humanized - administration & dosage (67) 67
article (67) 67
immunosuppressive agents - therapeutic use (67) 67
inhibitor eculizumab (67) 67
antibodies, monoclonal - therapeutic use (65) 65
glomerulonephritis (65) 65
urologic and male genital diseases (65) 65
dense deposit disease (64) 64
case report (63) 63
hemoglobinuria, paroxysmal - diagnosis (63) 63
thrombocytopenic purpura (63) 63
infant (62) 62
proteins (62) 62
antibodies (61) 61
prognosis (59) 59
complement inactivating agents - therapeutic use (57) 57
c3 glomerulopathy (56) 56
drug therapy (56) 56
renal-transplantation (55) 55
hus (54) 54
surgery (54) 54
hemoglobinuria, paroxysmal - therapy (53) 53
review (53) 53
complement activation - drug effects (52) 52
hemoglobinuria, paroxysmal - complications (52) 52
impact (51) 51
stem cells (51) 51
complement factor h - genetics (50) 50
urology (50) 50
factor-h (48) 48
hematopoietic stem cells (48) 48
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1102) 1102
German (20) 20
Spanish (17) 17
French (14) 14
Russian (9) 9
Japanese (4) 4
Polish (2) 2
Hungarian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 4, pp. 518 - 525
Abstract We recently observed that dysregulation of the complement system may be involved in the pathogenesis of hematopoietic stem cell... 
Hematology, Oncology and Palliative Medicine | Hematopoietic stem cell transplant | Eculizumab | Thrombotic microangiopathy | Eculizumab pharmacokinetics | CH50 | DIAGNOSIS | LONG-TERM SURVIVORS | COMPLEMENT | HEMOLYTIC-UREMIC SYNDROME | IMMUNOLOGY | TRANSPLANTATION | GLOMERULAR-FILTRATION-RATE | Hematopoietic stem cell | CYSTATIN-C | transplant | Eculizumab pharrnacokinetics | CHRONIC KIDNEY-DISEASE | HYPERTENSION | HEMATOLOGY | CHSO | Hematologic Neoplasms - therapy | Severity of Illness Index | Complement Hemolytic Activity Assay | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Hematologic Neoplasms - mortality | Humans | Child, Preschool | Complement Membrane Attack Complex - antagonists & inhibitors | Thrombotic Microangiopathies - mortality | Transplantation, Autologous | Hematologic Neoplasms - pathology | Transplantation, Homologous | Drug Dosage Calculations | Complement Inactivating Agents - therapeutic use | Hematopoietic Stem Cell Transplantation - adverse effects | Survival Analysis | Hematologic Neoplasms - immunology | Thrombotic Microangiopathies - etiology | Drug Monitoring | Child | Thrombotic Microangiopathies - immunology | Thrombotic Microangiopathies - drug therapy | Hypertension | Enzymes | Mortality | Stem cells | Transplantation | Children | Health aspects | Hematopoietic stem cells
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 11/2017, Volume 9, Issue 11, pp. 1558 - 1573
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 1, pp. 90 - 92
Journal Article